EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131

Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk iD, Sofia F Garcia iD, Carlos L Arteaga, William F Symmans, Ben H Park, Brian L Burnette, Della F Makower, Margaret Block, Kimberly A Morley und 13 weitere

Cancer · 2024

DOI: 10.1002/cncr.35187 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer, 2024. Verfasst von Karen L Smith und 24 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Capecitabine, Patient Reported Outcome Measures, Quality of Life, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patient‐reported outcomes (PROs) are a better tool for evaluating the experiences of patients who have symptomatic, treatment‐associated adverse events (AEs) compared with clinician‐rated AEs. The authors present PROs assessing health‐related quality of life (HRQoL) and treatment‐related neurotoxicity for adjuvant capecitabine versus platinum on the Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) EA1131 trial (ClinicalTrials.gov identifier NCT02445391).

Methods

Participants completed the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy–Breast Cancer Symptom Index (NFBSI‐16) and the Functional Assessment of Cancer Therapy–Gynecologic Oncology Group neurotoxicity subscale (platinum arm only) at baseline, cycle 3 day 1 (C3D1), 6 months, and 15 months. Because of early termination, power was insufficient to test the hypothesis that HRQoL, as assessed by the NFBSI‐16 treatment side‐effect (TSE) subscale, would be better at 6 and 15 months in the capecitabine arm; all analyses were exploratory. Means were compared by using t ‐tests or the Wilcoxon rank‐sum test, and proportions were compared by using the χ 2 test.

Results

Two hundred ninety‐six of 330 eligible patients provided PROs. The mean NFBSI‐16 TSE subscale score was lower for the platinum arm at baseline ( p = .02; absolute difference, 0.6 points) and for the capecitabine arm at C3D1 ( p = .04; absolute difference, 0.5 points), but it did not differ at other times. The mean change in TSE subscale scores differed between the arms from baseline to C3D1 (platinum arm, 0.15; capecitabine arm, −0.72; p = .03), but not from baseline to later time points. The mean decline in Functional Assessment of Cancer Therapy–Gynecologic Oncology Group neurotoxicity subscale scores exceeded the minimal meaningful change (1.38 points) from baseline to each subsequent time point (all p < .05).

Conclusions

Despite the similar frequency of clinician‐rated AEs, PROs identified greater on‐treatment symptom burden with capecitabine and complemented clinician‐rated AEs by characterizing patients’ experiences during chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabinePatient Reported Outcome MeasuresQuality of LifeTriple Negative Breast NeoplasmsAdultAgedFemaleHumansMiddle AgedChemotherapy, AdjuvantNeoplasm, ResidualPlatinum

Stichwörter der Autor:innen

adjuvant therapycapecitabineneuropathypatient‐reported outcomesplatinumquality of lifetriple‐negative breast cancer

Substanzen

CapecitabinePlatinum

Autor:innen und Institutionen

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA.
  • Sibley Memorial Hospital, Washington, District of Columbia, USA.
  • Dana Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Biostatistics Center, Boston, Massachusetts, USA.
  • Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA.
  • Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

ORCID-Profile: Amye J Tevaarwerk, Sofia F Garcia, Joseph A Sparano, Lynne I Wagner

Förderung

  • NCI NIH HHS

Zitieren

APA

Smith, K. L., Zhao, F., Mayer, I. A., Tevaarwerk, A. J., Garcia, S. F., Arteaga, C. L., Symmans, W. F., Park, B. H., Burnette, B. L., Makower, D. F., Block, M., Morley, K. A., Jani, C. R., Mescher, C., Dewani, S. J., Brown-Glaberman, U., Flaum, L. E., Mayer, E. L., Sikov, W. M., …, & Wagner, L. I. (2024). Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131. Cancer. https://doi.org/10.1002/cncr.35187

Vancouver

Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, et al. Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131. Cancer. 2024. doi:10.1002/cncr.35187

BibTeX
@article{Smith2024,
  author = {Smith, Karen L and Zhao, Fengmin and Mayer, Ingrid A and Tevaarwerk, Amye J and Garcia, Sofia F and Arteaga, Carlos L and Symmans, William F and Park, Ben H and Burnette, Brian L and Makower, Della F and Block, Margaret and Morley, Kimberly A and Jani, Chirag R and Mescher, Craig and Dewani, Shabana J and Brown-Glaberman, Ursa and Flaum, Lisa E and Mayer, Erica L and Sikov, William M and Rodler, Eve T and DeMichele, Angela M and Sparano, Joseph A and Wolff, Antonio C and Miller, Kathy D and Wagner, Lynne I},
  title = {Adjuvant platinum versus capecitabine for residual, invasive, triple‐negative breast cancer: Patient‐reported outcomes in ECOG‐ACRIN EA1131},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35187}
}
Kostenlos starten →